[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.
[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.
复制标题
[18F]在小鼠中用Belinostat治疗的Belinostat治疗后，FDG和[18F] FLT正电子发射断层扫描成像。
DOI：
10.1186/1471-2407-13-168
复制
发表时间：
2013-04-01
期刊：
影响因子：
3.8
通讯作者：
Kjær A
中科院分区：
文献类型：
--
作者：
Jensen MM;Erichsen KD;Johnbeck CB;Björkling F;Madsen J;Jensen PB;Sehested M;Højgaard L;Kjær A
贝力诺他是一种组蛋白脱乙酰酶抑制剂，在几个临床前肿瘤模型和临床试验中具有抗肿瘤作用。本研究的目的是应用3‘-脱氧-3’-[18F]氟代胸苷([18F]Flt)和2-脱氧-2-[18F]氟-D-葡萄糖([18F]FDG)正电子发射断层扫描(PET)技术，在活体卵巢癌模型中评价其对细胞增殖和葡萄糖摄取的影响。本文研究了白藜芦醇对人卵巢癌小鼠移植瘤(A2780)的体内摄取作用。将小鼠分成两组，分别给予比力诺(40 mg/kg，ip，每日两次，第0-4天和第6-10天)或赋形剂。基线[18F]Flt或[18F]FDG扫描在治疗前(第0天)进行，并在第3、6和第10天重复。示踪剂摄取使用小动物PET/CT进行量化。治疗后第10天，治疗组肿瘤体积为462 ± 62%(640 mm~3)，与对照组769 ± 74%(926 mm~3)相比，差异有统计学意义(P<0.011)。[18F]对照组的FLT SUVmax从基线到第10天逐渐升高(+30 ± 9%；P = 0.048)。治疗组未见明显升高。治疗组在第10天的[18F]FDG SUV平均值与对照组(P = 0.0023)有显著差异。在治疗组内，第3天的[18F]FDG摄取和较小程度的[18F]Flt摄取与第10天的肿瘤生长显著相关。开始治疗后早期的[18F]FDG摄取预测了第10天的肿瘤大小，提示[18F]FDG可能是一种有价值的生物标志物，可用于无创评估贝力诺的抗肿瘤活性。
Belinostat is a histone deacetylase inhibitor with anti-tumor effect in several pre-clinical tumor models and clinical trials. The aim of the study was to evaluate changes in cell proliferation and glucose uptake by use of 3’-deoxy-3’-[18F]fluorothymidine ([18F]FLT) and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) following treatment with belinostat in ovarian cancer in vivo models. In vivo uptake of [18F]FLT and [18F]FDG in human ovary cancer xenografts in mice (A2780) were studied after treatment with belinostat. Mice were divided in 2 groups receiving either belinostat (40 mg/kg ip twice daily Day 0–4 and 6–10) or vehicle. Baseline [18F]FLT or [18F]FDG scans were made before treatment (Day 0) and repeated at Day 3, 6 and 10. Tracer uptake was quantified using small animal PET/CT. Tumors in the belinostat group had volumes that were 462 ± 62% (640 mm3) at Day 10 relative to baseline which was significantly different (P = 0.011) from the control group 769 ± 74% (926 mm3). [18F]FLT SUVmax increased from baseline to Day 10 (+30 ± 9%; P = 0.048) in the control group. No increase was observed in the treatment group. [18F]FDG SUVmean was significantly different in the treatment group compared to the control group (P = 0.0023) at Day 10. Within treatment groups [18F]FDG uptake and to a lesser extent [18F]FLT uptake at Day 3 were significantly correlated with tumor growth at Day 10. [18F]FDG uptake early following treatment initiation predicted tumor sizes at Day 10, suggesting that [18F]FDG may be a valuable biomarker for non-invasive assessment of anti-tumor activity of belinostat.
登录
查看更多内容
影响因子：
4.7
作者：
Dizon DS;Blessing JA;Penson RT;Drake RD;Walker JL;Johnston CM;Disilvestro PA;Fader AN
通讯作者：
Fader AN
影响因子：
8.8
作者：
通讯作者：
--
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
11.5
作者：
Apisarnthanarax, Smith;Alauddin, Mian M.;Chao, K. S. Clifford
通讯作者：
Chao, K. S. Clifford
影响因子：
11.2
作者：
Leyton, J;Latigo, JR;Aboagye, EO
通讯作者：
Aboagye, EO